D.E. Shaw & Co
MRNS

D.E. Shaw & Co’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

D.E. Shaw & Co’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-178,801
Closed -$315K – 5067
2024
Q3 		$315K Buy
+178,801
New +$250K ﹤0.01% 3953
2023
Q4 		– Sell
-11,400
Closed -$91.8K – 4702
2023
Q3 		$91.8K Sell
11,400
-343,348
-97% -$2.86M ﹤0.01% 3862
2023
Q2 		$3.85M Buy
354,748
+266,521
+302% +$2.28M ﹤0.01% 2069
2023
Q1 		$609K Buy
+88,227
New +$553K ﹤0.01% 3454
2021
Q2 		– Sell
-17,203
Closed -$266K – 5092
2021
Q1 		$266K Buy
+17,203
New +$249K ﹤0.01% 3754
2020
Q3 		– Sell
-118,574
Closed -$1.21M – 4251
2020
Q2 		$1.21M Buy
+118,574
New +$1.09M ﹤0.01% 2793
2019
Q3 		– Sell
-4,579
Closed -$76K – 4069
2019
Q2 		$76K Buy
+4,579
New +$79.5K ﹤0.01% 3567

Other funds holding MRNS

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co's MRNS Position: Q4 2024 in Review

D.E. Shaw & Co sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2024, closing a stake of 178,801 shares — an estimated $315K sold.

D.E. Shaw & Co first reported a position in MRNS in Q2 2019 and held it in 7 quarters. The position peaked at $3.85M in Q2 2023. 53 funds tracked by Wall St. Rank hold MRNS as of Q4 2024.

  • D.E. Shaw & Co reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 178,801 Marinus Pharmaceuticals, Inc shares in Q4 2024, an estimated $315K.
  • D.E. Shaw & Co first reported a position in Marinus Pharmaceuticals, Inc in Q2 2019 and held it in 7 quarters.
  • D.E. Shaw & Co's Marinus Pharmaceuticals, Inc position peaked at $3.85M in Q2 2023.
  • 53 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2024.

Based on D.E. Shaw & Co's 13F filing for Q4 2024, filed 14 Feb 2025.